Wegovy is associated with increasing risk of hair loss, studies show

A version of this article first appeared in the CNBC’s healthy return newsletter, which brings the latest health care news directly to your inbox. Subscribe here To achieve future versions.

Still another study is zero on unexpected side effects Novo nordiskKamaglutide – Active component in the company’s blockbuster weight loss drug vegovi and diabetes treatment ozmpic.

But this time, the study highlights the risk of hair loss.

To be clear, the link of semaglutide to hair loss is not new. The clinical trials conducted by Novo Nordisk have shown a greater risk of hair loss in patients who took semaglutide compared to those who take a placebo.

Vagovi and ozmpic are part of a square of popular drugs called GLP -1s, which mimic a hormone in the intestine to press hunger and regulate blood sugar. Those drugs are known for their gastrointestinal side effects such as nausea and vomiting, and some patients have also investigated after informing them to experience stomach paralysis and suicide thoughts.

In a statement, Novo Nordisk stated that it is “reassured in our GLP-1 profit-risk profile, when their signs and products are used to line up.”

New studies, which have been performed by researchers at the University of British Columbia and not yet presented for peer reviews, suggests that semaglutide is associated with hair loss compared to users of an old weight loss pellet, called contrave, or bupropian-neltrexone.

Researchers examined data of 16 million patients from 2006 to 2020 and 1,926 Semglutide users and 1,348 control users identified. People with diagnosis or who used antihyperglycemics – drugs, which reduce blood sugar levels – were excluded.

Hair loss phenomenon rates were higher than control users among semaglutide users. Overall, patients who took semaglutide had 52% higher risk of hair loss than those who had contracted.

Researchers also found that women who took semaglutides were two times higher at the controversy group than women. But one of the authors, Mohit Sodi told CNBC that “most of our data was operated by women” so they could not compare men versus women in the study.

Those who used to take semaglutide had 22 cases of hair loss in women and there was only one case in men. Future studies with large sample sizes of patients need to determine whether there is a difference between men and women, Sodhi said.

According to Sodhi, the researchers also did not follow the patients, if they prevent semaglutide or contraave, so it is not clear that the risk of hair loss is reduced, then they get away from the Novo Nordisk drug. More research is required in that area, he said.

So, why can semaglutide cause a greater risk of hair loss?

A factor can occur physical stress that can be inspired by rapid weight loss, which can “disintegrate the natural halls cycle” according to the soda. He said that it can have a more major effect of semaglutide as it is known to reduce weight faster than the contrave.

Semaglutide’s ability to suppress appetite also leads to patients who consume less food, which can possibly cause nutrient deficiencies, especially including protein, Sodhi said. He said that protein deficiency has been associated with hair loss.

Sodhi said that patients can also lose nutrients through vomiting on semaglutide. Some health experts also envisage that semaglutide may give rise to hormonal shifts that increase the risk of a common form of hair loss called Androgenic alopecia, they said.

Researchers said in the study that people, and especially women, and considering using semaglutides for weight loss, may want to do “factor as a possible range in hair loss”, considering using semaglutide for weight loss. Researchers stated that people with diabetes or sick obesity can weigh their risks and benefits differently, and may be more inclined to accept hair loss as potential risk.

One of the study authors, Dr. Mahayar Itminen has consulted on the first ozemic litigation.

Feel free to send any suggestions, suggestions, story ideas and data to Annika at Annikakim.constantino@nbcuni.com.

Dexcom After inspecting the company’s manufacturing facilities at San Diego, California and Messa, Arizona, a warning letter was received from the US Food and Drug Administration last week.

According to Friday’s company with US Securities and Exchange Commission, FDA “saw non-non-renovations” with the FDA’s quality management system and manufacturing procedures. The agency also noted that the company’s response to its list of its comments, formally known as Form 483, was insufficient.

Dexcom said in the filing, “The company takes the cases identified in the warning seriously, already submitted several reactions to Form 483 and is in the process of preparing a written response for the warning letter.”

It was not clear what FDA identified specific problems in facilities.

Dexcom produces devices called continuous glucose monitors that can help users to track their blood sugar and manage diabetes. The FDA warning letter does not limit Dexcom’s ability to manufacture or distribute its products.

The company told CNBC that it is “updating the FDA regularly” about the improvement of FDA, as the agency inspected last year. Dexcom said that some of its observations have already been adequately addressed, and the warning letter has “extended specific areas for continuous attention.”

The company said in a statement, “Dexcom is standing behind the quality of our products and is committed to solving any outstanding question from the FDA as soon as possible.”

Dexcom also appointed Renee Gala, Chief Operating Officer of Jazz Pharmaceuticals in its board of directors last week. Gala has acted in her current role since 2023, and she first served as the Chief Financial Officer in Jazz.

He has also played leadership roles in Grill and Theravan Biofarma, and he has spent many years in Pharmaceutical giant Elli Lily.

Daxcom CEO Kevin Sear said in a release, “Reni’s widespread experience offers an excellent fit at this important point in DEXCom’s journey to promote growth and shareholder value, including commercial and R&D to guide global finance and global operations.

As Intrade Trading on Tuesday morning, Dexcom’s shares are about 9% below till date.

Read the entire release here.

Feel free to send any suggestions, tips, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.